Sai Life Sciences announced the approval of its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results on February 5, 2026. Standalone profit after tax for the quarter stood at ₹976.30 million. Consolidated profit after tax for the quarter reached ₹1,003.75 million. The Board also granted employee stock options.
Financial Performance
The company’s board of directors reviewed and approved the unaudited financial results. Key highlights from the standalone results for the quarter ended December 31, 2025 include:
- Total Income: ₹5,576.26 million
- Profit Before Tax: ₹1,304.69 million
- Profit After Tax: ₹976.30 million
For the consolidated results for the same period:
- Total Income: ₹5,648.44 million
- Profit Before Tax: ₹1,341.66 million
- Profit After Tax: ₹1,003.75 million
Exceptional Items
The results reflect an ₹82.93 million loss categorized as an exceptional item. This is primarily due to an increase in gratuity and leave liabilities following the Indian government’s notification of new labor codes.
Employee Stock Options
During the quarter, the Nomination and Remuneration Committee approved the grant of 205,000 employee stock options (ESOPs) under the company’s Management ESOP Scheme – 2018, effective November 13, 2025. A portion of these options will vest over four years, while the remainder vests over five years.
IPO Proceeds Utilization
The company has utilized ₹7,200.00 million towards repayment/prepayment of borrowings and ₹1,898.84 million towards general corporate purposes from its IPO proceeds. This leaves no unutilized funds as of December 31, 2025.
Source: BSE
